Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.
Yoshihiko TasakiNanami ItoYoshihisa MimuraYosuke SugiyamaRyo OgawaTakaya ShimuraMotoki NakamuraDaisuke KawakitaShuzo HamamotoTakehiro UemuraKeisuke YokotaMoeko IidaKunihiro OdagiriYuka KimuraYuji HottaHirokazu KomatsuKatsuhiro OkudaAkio NiimiTakahiro YasuiShinichi IwasakiAkimichi MoritaHiromi KataokaShuji TakiguchiYoko Furukawa-HibiPublished in: Asia-Pacific journal of clinical oncology (2024)
Collectively, our findings suggest that nivolumab 480 mg every 4 weeks may be more effective than nivolumab 240 mg every 2 weeks in terms of economic impact.